

30.01.2026

To,  
National Stock Exchange of India Limited  
"Exchange Plaza",  
Bandra-Kurla Complex,  
Bandra (East) Mumbai 400 051

BSE Limited  
Floor- 25, P J Tower,  
Dalal Street,  
Mumbai 400 001

**SYMBOL:- EPIGRAL**

**Scrip Code: 543332**

Dear Sirs,

**Sub.: Press Release on Un-Audited Financial Results – Q3 FY26**

**Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

---

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release on Un-Audited Financial Results – Q3 FY26.

The said Press Release is also available at [www.epigral.com](http://www.epigral.com) in the Investor Relations section.

This is for information and records.

Thanking you,

Yours faithfully,

**For Epigral Limited**

**Gaurang Trivedi**  
**Company Secretary & Compliance Officer**  
**M. No. 22307**



**Epigral Limited**

Epigral Tower, Behind Safal Profitaire, Corporate Road  
Prahladnagar, Ahmedabad 380015, Gujarat, India.

**T** +91 79 2970 9600

**E** [info@epigral.com](mailto:info@epigral.com)

**W** [epigral.com](http://epigral.com)

## **Press Release**

### **Epigral Limited's Q3FY26 Revenue stood at ₹ 603 Crore**

**January 30, 2026:** Epigral Limited (Epigral), India's leading integrated chemical manufacturer, today announced its financial results for the quarter ended December 31, 2025. The company posted a revenue of ₹ 603 Crore for the quarter ended December 31<sup>st</sup>, 2025 as against ₹ 649 Crore recorded in Q3FY25. During the quarter under review, PAT stood at ₹ 39 Crore compared to ₹ 104 Crore in Q3FY25.

**Commenting on the results Mr. Maulik Patel; Chairman and Managing Director – Epigral** said: *"This quarter delivered marginal sequential topline growth. While demand softened before mid-November due to extended monsoon conditions, the market has strengthened notably since then, and we anticipate sustained positive momentum ahead.*

*Margins in Q3FY26 reflected temporary pressures from softer realizations on select products, elevated raw material costs, and inventory dynamics. With the improving market scenario, we anticipate positive outcomes starting Q4FY26.*

*Our capacity expansion projects for CPVC, Epichlorohydrin, and Wind Solar Hybrid Power Plant are progressing smoothly on schedule, set for timely commissioning. These initiatives will drive growth from FY27 onwards. We're also advancing new projects and look forward to sharing updates soon.*

*We remain committed to our journey of scalable, profitable growth—optimizing capital allocation, enhancing integration, and delivering lasting value for all stakeholders."* Mr Patel added.

#### **The key performance highlights:**

##### **Q3FY26 Key Highlights:**

- Plant utilization stood at 78% similar to previous quarter
- QoQ Revenue increased by 2% to ₹ 603 Cr with 52% revenue from Derivatives and Specialty business
- EBITDA margin stood at 17% vs 23% in Q2FY26 on account of drop in realizations and increase in cost of raw materials
- PAT stood at ₹ 39 Cr vs ₹ 51 Cr in Q2FY26

##### **9MFY26 Key Highlights:**

- Plant utilization stood at 76% vs 82% in 9MFY25
- Sales volume dropped in 9MFY26 majorly on account of subdued demand because of extended monsoon and lower volume because of maintenance work at plant
- Revenue dropped by 7% to ₹ 1,807 Cr with 51% revenue from Derivatives & Specialty business
- EBITDA margin stood at 22% vs 28% in 9MFY25 on account of drop in realizations and increase in raw material prices
- Net Debt stood at ₹ 557 Cr vs ₹ 521 Cr as on 31<sup>st</sup> December 2025
- ROCE stood at 17% and Net Debt/EBITDA stood at 1.0x

##### **Strategic Updates:**

- Epigral spent ₹ 337 Cr on capex in 9MFY26
- Epigral Capex plans are moving as per schedule and are expected to get commissioned within the timeline and budget

- CPVC Resin capacity will reach to 1,50,000 TPA, by adding additional 75,000 TPA
- Epichlorohydrin capacity will reach to 1,00,000 TPA, by adding additional 50,000 TPA
- Wind Solar Hybrid Power Plant capacity will reach to 38.14 MW, by adding additional 19.80 MW
- Epigral commissioned India's 1<sup>st</sup> Chlorotoluenes Value Chain plant in March 2025.

#### **About Epigral Limited**

Epigral Limited (Epigral), incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral's Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure. In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.

Epigral is strengthening its position in the specialty chemical business by enhancing its capacity its CPVC and ECH capacity, venturing into the Chlorotoluenes value chain and dedicated R&D centre. The company is focused on sustainable value creation for all its stakeholders.

Through integral collaborations and exceptional solutions, Epigral strives to enhance value and exceed expectations, leaving an indelible mark on stakeholders and the industry.